MET and liver cancer: In addition, the combination treatment of Cabozantinib and IL-32γ overexpression further increased the expression of autophagy-related markers and p-ULK1; however, the expression levels of MET, p-mTOR, and mTOR-related proteins further decreased in liver cancer cell lines.